CA2984010A1 - Multimeric protein purity determination - Google Patents
Multimeric protein purity determination Download PDFInfo
- Publication number
- CA2984010A1 CA2984010A1 CA2984010A CA2984010A CA2984010A1 CA 2984010 A1 CA2984010 A1 CA 2984010A1 CA 2984010 A CA2984010 A CA 2984010A CA 2984010 A CA2984010 A CA 2984010A CA 2984010 A1 CA2984010 A1 CA 2984010A1
- Authority
- CA
- Canada
- Prior art keywords
- ligand
- homodimer
- subunit
- seq
- capillary
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
- G01N21/33—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using ultraviolet light
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2201/00—Features of devices classified in G01N21/00
- G01N2201/06—Illumination; Optics
- G01N2201/061—Sources
- G01N2201/06113—Coherent sources; lasers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/416—Systems
- G01N27/447—Systems using electrophoresis
- G01N27/44704—Details; Accessories
- G01N27/44717—Arrangements for investigating the separated zones, e.g. localising zones
- G01N27/44721—Arrangements for investigating the separated zones, e.g. localising zones by optical means
- G01N27/44726—Arrangements for investigating the separated zones, e.g. localising zones by optical means using specific dyes, markers or binding molecules
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/416—Systems
- G01N27/447—Systems using electrophoresis
- G01N27/44756—Apparatus specially adapted therefor
- G01N27/44795—Isoelectric focusing
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Optics & Photonics (AREA)
- Food Science & Technology (AREA)
- Peptides Or Proteins (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562160341P | 2015-05-12 | 2015-05-12 | |
| US62/160,341 | 2015-05-12 | ||
| PCT/US2016/031899 WO2016183222A1 (en) | 2015-05-12 | 2016-05-11 | Multimeric protein purity determination |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2984010A1 true CA2984010A1 (en) | 2016-11-17 |
Family
ID=56072452
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2984010A Pending CA2984010A1 (en) | 2015-05-12 | 2016-05-11 | Multimeric protein purity determination |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US10520511B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3294775B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP7240812B2 (cg-RX-API-DMAC7.html) |
| AR (1) | AR104610A1 (cg-RX-API-DMAC7.html) |
| AU (2) | AU2016261854B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2984010A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2881359T3 (cg-RX-API-DMAC7.html) |
| MA (2) | MA56416A (cg-RX-API-DMAC7.html) |
| PL (1) | PL3294775T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016183222A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121253411A (zh) | 2015-11-30 | 2026-01-02 | 因塔生物有限责任公司 | 用于样品表征的装置和方法 |
| CN109937034B (zh) | 2016-11-21 | 2022-09-16 | 济世-伊沃泰克生物制品有限公司 | 阿柏西普制剂及其用途 |
| MY199833A (en) | 2017-08-17 | 2023-11-24 | Just Evotec Biologics Inc | Method of purifying glycosylated protein from host cell galectins and other contaminants |
| MY202872A (en) | 2017-11-20 | 2024-05-28 | Just Evotec Biologics Inc | Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof |
| CA3089842A1 (en) | 2018-01-29 | 2019-08-01 | Intabio, Inc. | Devices, methods and kits for sample characterization |
| EP3811397B1 (en) | 2018-05-31 | 2024-09-18 | Intabio, Llc | Methods for interfacing microfluidic systems with mass spectrometry |
| WO2020055832A1 (en) * | 2018-09-10 | 2020-03-19 | Genentech, Inc. | Systems and methods for affinity capillary electrophoresis |
| US11782023B2 (en) * | 2018-12-19 | 2023-10-10 | Regeneron Pharmaceuticals, Inc. | Ce-western applications for antibody development |
| CA3126712A1 (en) * | 2019-01-31 | 2020-08-06 | Regeneron Pharmaceuticals, Inc. | Native microfluidic ce-ms analysis of antibody charge heterogeneity |
| US12594557B2 (en) | 2019-08-12 | 2026-04-07 | Intabio, Llc | Isoelectric focusing devices and fixtures |
| US11285484B2 (en) | 2019-08-12 | 2022-03-29 | Intabio, Llc | Multichannel isoelectric focusing devices and high voltage power supplies |
| JP2024513950A (ja) * | 2021-04-14 | 2024-03-27 | ディーエイチ テクノロジーズ デベロップメント プライベート リミテッド | キャピラリー電気泳動におけるタンパク質分析のための天然蛍光検出 |
| CN118284809A (zh) * | 2021-11-25 | 2024-07-02 | 豪夫迈·罗氏有限公司 | 少量抗体副产物的定量 |
| WO2024123698A1 (en) * | 2022-12-08 | 2024-06-13 | Regeneron Pharmaceuticals, Inc. | Methods to characterizing a fragment crystallizable domain of a bispecific antibody |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPP385598A0 (en) * | 1998-06-02 | 1998-06-25 | Life Therapeutics Limited | Purification of antibodies |
| US6472179B2 (en) * | 1998-09-25 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Receptor based antagonists and methods of making and using |
| US6818112B2 (en) * | 1999-04-20 | 2004-11-16 | Target Discovery, Inc. | Protein separation via multidimensional electrophoresis |
| JP4723725B2 (ja) * | 1999-04-20 | 2011-07-13 | ターゲット ディスカバリー, インコーポレイテッド | 代謝経路を分析するための方法 |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| AUPQ743300A0 (en) * | 2000-05-11 | 2000-06-01 | Life Therapeutics Limited | Separation of avian antibodies |
| US6927004B2 (en) | 2002-03-08 | 2005-08-09 | Asml Netherlands B.V. | Mask for use in lithography, method of making a mask, lithographic apparatus, and device manufacturing method |
| WO2007034907A1 (ja) * | 2005-09-22 | 2007-03-29 | Chemicals Evaluation And Research Institute | 被検化学物質の生物に与える影響の予測方法 |
| EP1803814A1 (en) * | 2005-12-27 | 2007-07-04 | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. | Method of improving the antibody selection capacity in phage-display library |
| JP5144499B2 (ja) * | 2006-03-31 | 2013-02-13 | 中外製薬株式会社 | 二重特異性抗体を精製するための抗体改変方法 |
| DK2150617T3 (en) | 2007-06-04 | 2015-01-12 | Regeneron Pharma | Regions with increased expression and stability |
| EP3127921A1 (en) * | 2007-09-26 | 2017-02-08 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substition in cdr |
| JP4977588B2 (ja) * | 2007-12-07 | 2012-07-18 | 富士フイルム株式会社 | イムノクロマトグラフ方法 |
| TWI507525B (zh) | 2009-06-26 | 2015-11-11 | Regeneron Pharma | 具天然免疫球蛋白形式之易分離的雙專一性抗體 |
| US9376495B2 (en) * | 2011-05-21 | 2016-06-28 | Macrogenics, Inc. | Deimmunized serum-binding domains and their use in extending serum half-life |
| GB2504139B (en) * | 2012-07-20 | 2014-12-31 | Argen X Bv | Antibodies to highly conserved targets produced by the immunisation of Camelidae species |
| EP2604624A1 (en) * | 2011-12-13 | 2013-06-19 | University College Dublin National University Of Ireland, Dublin | Bowman-Birk protease Inhibitor (BBI) binding peptides, and uses thereof in the separation, detection or purification of BBI. |
| EP3517548A1 (en) * | 2012-03-13 | 2019-07-31 | NovImmune S.A. | Readily isolated bispecific antibodies with native immunoglobulin format |
| SG10201609535TA (en) | 2012-06-05 | 2017-01-27 | Regeneron Pharma | Methods for making fully human bispecific antibodies using a common light chain |
| TWI864338B (zh) | 2012-11-14 | 2024-12-01 | 美商再生元醫藥公司 | 重組細胞表面捕捉蛋白質 |
| CN118271429A (zh) * | 2013-08-19 | 2024-07-02 | 豪夫迈·罗氏有限公司 | 用羟基磷灰石层析分离双特异性抗体和双特异性抗体生产副产物 |
| EP3041865A2 (en) * | 2013-09-03 | 2016-07-13 | NovImmune S.A. | Readily isolated bispecific binding molecules with native format having mutated constant regions |
-
2016
- 2016-05-11 EP EP16724805.3A patent/EP3294775B1/en active Active
- 2016-05-11 ES ES16724805T patent/ES2881359T3/es active Active
- 2016-05-11 JP JP2017558949A patent/JP7240812B2/ja active Active
- 2016-05-11 AU AU2016261854A patent/AU2016261854B2/en active Active
- 2016-05-11 WO PCT/US2016/031899 patent/WO2016183222A1/en not_active Ceased
- 2016-05-11 US US15/152,135 patent/US10520511B2/en active Active
- 2016-05-11 CA CA2984010A patent/CA2984010A1/en active Pending
- 2016-05-11 EP EP21171963.8A patent/EP3885368A1/en not_active Withdrawn
- 2016-05-11 MA MA056416A patent/MA56416A/fr unknown
- 2016-05-11 PL PL16724805T patent/PL3294775T3/pl unknown
- 2016-05-11 MA MA043987A patent/MA43987A/fr unknown
- 2016-05-12 AR ARP160101379A patent/AR104610A1/es unknown
-
2019
- 2019-11-18 US US16/686,770 patent/US12158473B2/en active Active
-
2021
- 2021-06-02 JP JP2021092988A patent/JP7137663B2/ja not_active Expired - Fee Related
-
2022
- 2022-05-05 AU AU2022203033A patent/AU2022203033B2/en not_active Expired - Fee Related
- 2022-09-02 JP JP2022139802A patent/JP2022171730A/ja active Pending
-
2024
- 2024-04-16 US US18/637,343 patent/US20240280587A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MA43987A (fr) | 2018-12-19 |
| US20240280587A1 (en) | 2024-08-22 |
| AU2022203033B2 (en) | 2025-06-26 |
| WO2016183222A4 (en) | 2017-01-05 |
| AU2022203033A1 (en) | 2022-05-26 |
| ES2881359T3 (es) | 2021-11-29 |
| US10520511B2 (en) | 2019-12-31 |
| US12158473B2 (en) | 2024-12-03 |
| JP7137663B2 (ja) | 2022-09-14 |
| HK1252480A1 (zh) | 2019-05-24 |
| AU2016261854A1 (en) | 2017-11-09 |
| MA56416A (fr) | 2022-05-04 |
| EP3885368A1 (en) | 2021-09-29 |
| JP2021152544A (ja) | 2021-09-30 |
| EP3294775B1 (en) | 2021-07-14 |
| JP2022171730A (ja) | 2022-11-11 |
| US20170045527A1 (en) | 2017-02-16 |
| AU2016261854B2 (en) | 2022-05-26 |
| JP7240812B2 (ja) | 2023-03-16 |
| US20200166522A1 (en) | 2020-05-28 |
| AR104610A1 (es) | 2017-08-02 |
| EP3294775A1 (en) | 2018-03-21 |
| WO2016183222A1 (en) | 2016-11-17 |
| PL3294775T3 (pl) | 2021-12-13 |
| JP2018528389A (ja) | 2018-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240280587A1 (en) | Multimeric protein purity determination | |
| JP2021152544A6 (ja) | 多量体タンパク質の純度の決定 | |
| AU2016312909B2 (en) | Method for the reduction of host cell proteins in affinity chromatography | |
| JP7527273B2 (ja) | 多量体タンパク質の量および純度を決定するための方法およびクロマトグラフィーシステム | |
| JP2018525407A (ja) | 低伝導率洗浄緩衝液を用いたアフィニティークロマトグラフィー精製方法 | |
| CN113272651B (zh) | 鉴别蛋白质中的游离巯基的方法 | |
| JP2022532795A (ja) | ホスト細胞タンパク質の同定および定量方法 | |
| JP2018525408A (ja) | アフィニティークロマトグラフィーにおける宿主細胞タンパク質の低減方法 | |
| ES3041610T3 (en) | Systems and methods for affinity capillary electrophoresis | |
| HK40059237A (en) | Multimeric protein purity determination | |
| HK1252480B (en) | Multimeric protein purity determination | |
| EP4136121B1 (en) | Systems, materials, and methods for reversed-phase high performance liquid chromatography (rp-hplc) for monitoring formation of multi-specific molecules | |
| HK40050332B (en) | Systems and methods for affinity capillary electrophoresis | |
| BR112018001511B1 (pt) | Uso de solução aquosa com baixa condutividade e métodos de produção e purificação de anticorpos de isotipo igg1 ou igg4 humano |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20210506 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20241028 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250221 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250225 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD Year of fee payment: 9 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250423 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250423 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250702 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250702 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260609 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260609 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260622 |